Aphidicolin

Aphidicolin

SCHEMBL20771749

CN(N=O)C(N)=O.CN1CCNCC1.C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@@]12CC[C@]3(O)CO

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.61
▸ POLA1 P09884 1/20 0.61
▸ HTT P42858 1/20 0.61
▸ RECQL P46063 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ HIF1A Q16665 1/20 0.61
▸ CYP2C19 P33261 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aphidicolin SCHEMBL20770430 0.91 POLA1 (0.74) LMNAPOLA1HTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL16610406 0.78 POLA1 (1.00) LMNAPOLA1HTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL183956 0.78 POLA1 (1.00) LMNAPOLA1HTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL8763668 0.78 POLA1 (1.00) LMNAPOLA1HTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL14667945 0.78 POLA1 (1.00) LMNAPOLA1HTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL2332951 0.72 POLA1 (0.59) LMNAPOLA1HTTRECQLSMN1; SMN2
Hydrochloric Acid SCHEMBL29351943 0.70 CYP2C19 (0.98) LMNAPOLA1HTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL20771139 0.70 POLA1 (0.71) LMNAPOLA1HTTRECQLSMN1; SMN2
SCHEMBL14552897 0.66 LMNA (0.73) LMNAPOLA1HTTRECQLSMN1; SMN2
SCHEMBL15747 0.65 CYP2C19 (0.70) LMNAPOLA1HTTRECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019046303-A1 A METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2019-03-07 — — WO disclosed
Send feedback